Investigations for Amenorrhea: Understanding the Different Tests

Amenorrhea, or the absence of menstrual periods, can be caused by a variety of factors. To determine the underlying cause, several investigations may be necessary. Here are some of the tests that may be ordered and what they can reveal:

Transvaginal ultrasound scan: This test is useful for diagnosing polycystic ovarian syndrome (PCOS), which is a common cause of amenorrhea. The presence of 12 or more follicular cysts in both ovaries measuring 2 to 9 mm and increased ovarian stroma is sufficient to make the diagnosis.

Pituitary MRI: This test is used if a pituitary adenoma is suspected as a cause of amenorrhea. In that case, however, FSH and LH would be suppressed.

17-OH progesterone levels: This test is used as screening for congenital adrenal hyperplasia (CAH), which can cause amenorrhea in some cases.

Adrenal ultrasound scan: This test is used to detect adrenal tumors, which can cause hormonal imbalances that lead to amenorrhea.

Karyotyping: This test is performed when a genetic cause for primary ovarian insufficiency is suspected, such as fragile X mutation.

Understanding what each test can reveal can help healthcare providers determine the most appropriate course of treatment for their patients with amenorrhea.

Treatment Priorities for Pituitary Dysfunction

Patients with pituitary dysfunction require hormone replacement therapy to manage their symptoms. In cases of pan-hypopituitarism, corticosteroid replacement with hydrocortisone is essential to avoid adrenal crisis. Sex hormone replacement with oestrogen is important for bone health, while growth hormone replacement can address fatigue and muscle loss. Thyroxine replacement is also necessary but should be started after hydrocortisone to prevent adrenal crisis. Fludrocortisone is only needed for patients with adrenal insufficiency and blood pressure control issues. Prioritizing hormone replacement therapy can help manage symptoms and prevent complications in patients with pituitary dysfunction.

Autoimmune Polyglandular Syndrome: Types and Differential Diagnosis

Autoimmune polyglandular syndrome (APS) is a rare disorder characterized by the malfunction of multiple endocrine glands due to autoimmune-mediated damage. There are three types of APS, each with a distinct set of symptoms and glandular involvement.

APS Type 1 is characterized by chronic mucocutaneous candidiasis, hypoparathyroidism, and autoimmune adrenal insufficiency. APS Type 2 is the most common form and presents with Addison’s disease along with autoimmune thyroid disease and/or type 1 diabetes mellitus. APS Type 3 is associated with autoimmune thyroiditis, in conjunction with diabetes mellitus, pernicious anemia, or vitiligo.

In this case, the patient’s symptoms are consistent with a diagnosis of Addison’s disease, which is a hallmark of APS Type 2. Pituitary failure, renal tubular acidosis Type IV, and other autoimmune disorders such as Hashimoto’s thyroiditis can be ruled out based on the patient’s clinical presentation and laboratory findings.

In conclusion, APS should be considered in patients with multiple endocrine gland dysfunction, and a thorough differential diagnosis should be performed to determine the specific type of APS and guide appropriate treatment.

If treatment with fluids and pamidronate is unsuccessful, subcutaneous calcitonin may be used to manage refractory hypercalcaemia of malignancy.

Calcitonin is effective when used in combination with hydration, bisphosphonates, and/or denosumab, all of which have been administered to the patient in question. Its mechanism of action involves increasing renal calcium excretion and reducing bone resorption.

Denosumab is also commonly used in malignancy-associated hypercalcaemia and can be used in emergency situations. However, since the patient received a dose of denosumab the day before, administering another dose would not be appropriate.

Administering another dose of pamidronate would also be inappropriate since the last dose was given three days ago. Bisphosphonates take several days to take effect, and their maximum effect may not be seen until the seventh day.

While loop diuretics can be used to manage hypercalcaemia, thiazide-like diuretics such as indapamide should be avoided as they can worsen hypercalcaemia.

Steroids such as prednisolone are not effective in managing hypercalcaemia unless it is associated with sarcoidosis.

Managing Hypercalcaemia

Hypercalcaemia can be managed through various methods. The first step is to rehydrate the patient with normal saline, usually at a rate of 3-4 litres per day. Once rehydration is achieved, bisphosphonates can be administered. These drugs take 2-3 days to work, with maximum effect seen at 7 days.

Calcitonin is another option that can be used for quicker effect than bisphosphonates. In cases of sarcoidosis, steroids may also be used. However, loop diuretics such as furosemide should be used with caution as they may worsen electrolyte derangement and volume depletion. They are typically reserved for patients who cannot tolerate aggressive fluid rehydration.

In summary, the management of hypercalcaemia involves rehydration with normal saline followed by the use of bisphosphonates, calcitonin, or steroids in certain cases. Loop diuretics may also be used, but with caution. It is important to monitor electrolyte levels and adjust treatment accordingly.

Adrenal Insufficiency as the Likely Cause of Hyponatraemia, Weight Loss, and Skin Pigmentation

Hyponatraemia, weight loss, and skin pigmentation are symptoms that suggest a diagnosis of adrenal insufficiency. The initial management for this condition is steroid replacement. The most probable cause of this condition is autoimmune adrenal failure. Serum potassium levels may not be elevated due to gastrointestinal loss caused by vomiting.

Fluid restriction and demeclocycline are not appropriate treatments for this condition as it is unlikely that the hyponatraemia is related to syndrome of inappropriate antidiuretic hormone secretion (SIADH). Vasopressin is a treatment for cranial diabetes insipidus, which is not the case for this patient. While the patient may require IV fluids due to dehydration, normal saline is not the primary treatment.

In summary, adrenal insufficiency is the likely cause of the patient’s symptoms. Steroid replacement is the initial management, and other treatments such as fluid restriction and demeclocycline are not appropriate. Vasopressin is not a suitable treatment for this condition, and normal saline is not the primary treatment for dehydration.

Diagnosis of Hypogonadotrophic Hypogonadism

This patient presents with hypogonadotrophic hypogonadism, hirsutism, and a slightly elevated testosterone level. The possible causes of this condition include non-classical congenital adrenal hyperplasia (CAH) and Cushing’s syndrome. To diagnose non-classical CAH, a 17-OHP concentration above 33 nmol/L is required. On the other hand, a urine free cortisol test can provide useful information for diagnosing Cushing’s syndrome.

This is not a case of polycystic ovary syndrome (PCOS) or primary ovarian problem since the patient’s LH and FSH levels are normal, and oestradiol levels are low, indicating hypogonadotrophic hypogonadism. In contrast, PCOS is characterized by normal oestradiol levels. Pregnancy is also ruled out since high oestradiol and prolactin levels are expected in this condition. An ovarian testosterone-secreting tumor is also unlikely since it would result in much higher testosterone levels.

Further investigation revealed that the patient has non-classical CAH, which is most commonly caused by a defect in 21 hydroxylase. This condition can present at birth with salt wasting syndrome and ambiguous genitalia, during childhood with precocious puberty, or in adulthood with primary or secondary amenorrhoea and hirsutism.

A female with type 1 diabetes has developed Addisons disease, which explains her hypoglycaemic attacks, decreased insulin requirement, fatigue, and weight loss. This is a feature of Schmidt’s disease, a type 2 autoimmune polyendocrine syndrome. The diagnosis is confirmed through the short synacthen test. It is important to treat with hydrocortisone before replacing thyroxine to avoid Addisonian crisis. The patient also has hypogonadotrophic hypogonadism, indicated by low T4, raised TSH, high calcium, low FSH, low LH, and low oestradiol.

Understanding Addisonian Crisis and Its Management

Addisonian crisis is a medical emergency that occurs when the adrenal glands suddenly stop functioning properly. This can be caused by various factors such as sepsis, surgery, adrenal haemorrhage, or steroid withdrawal. The condition is characterized by symptoms such as severe weakness, low blood pressure, dehydration, and electrolyte imbalances.

To manage Addisonian crisis, immediate medical attention is required. The first step is to administer hydrocortisone, either intravenously or intramuscularly, at a dose of 100 mg. This should be followed by the infusion of normal saline or dextrose if the patient is hypoglycaemic. Hydrocortisone should be continued every 6 hours until the patient is stable. Fludrocortisone is not required as high cortisol levels exert weak mineralocorticoid action.

After 24 hours, oral replacement therapy may begin and gradually reduced to maintenance over 3-4 days. It is important to monitor the patient’s electrolyte levels and blood pressure during this time. With prompt and appropriate management, most patients with Addisonian crisis can recover fully.

Hormone replacement therapy (HRT) has been found to increase the risk of deep vein thrombosis (DVT) in women by 2-4 times, according to the Women’s Health Initiative (WHI) clinical trial. The trial was stopped 3 years early due to the increased dangers associated with HRT, particularly in older and obese women. However, thinner and younger women still had a higher risk of DVT when taking HRT compared to those taking a placebo. On the other hand, HRT has been found to have no effect on the risk of DVT and does not reduce the risk of coronary artery disease, according to the Heart and Oestrogen/Progestin Replacement Study (HERS). The WHO also found that HRT can increase the risk of ischaemic stroke due to an increased risk of blood clotting.

Patients who have been taking prednisolone at a dosage of 40 mg or higher for a duration of 7 days or longer, or at a dosage of 20 mg or higher for a duration of 14 days or longer, are considered to have compromised immune systems.

Corticosteroids are commonly prescribed medications that can be taken orally or intravenously, or applied topically. They mimic the effects of natural steroids in the body and can be used to replace or supplement them. However, the use of corticosteroids is limited by their numerous side effects, which are more common with prolonged and systemic use. These side effects can affect various systems in the body, including the endocrine, musculoskeletal, gastrointestinal, ophthalmic, and psychiatric systems. Some of the most common side effects include impaired glucose regulation, weight gain, osteoporosis, and increased susceptibility to infections. Patients on long-term corticosteroids should have their doses adjusted during intercurrent illness, and the medication should not be abruptly withdrawn to avoid an Addisonian crisis. Gradual withdrawal is recommended for patients who have received high doses or prolonged treatment.

Diagnosis of Anorexia Nervosa

This patient’s symptoms suggest a diagnosis of anorexia nervosa. The low BMI, excessive exercise, and amenorrhoea due to hypogonadotropic hypogonadism are all common features of this eating disorder. Additionally, the mild hyperprolactinaemia seen in this patient is often observed in individuals with anorexia and is unlikely to be caused by a microprolactinoma at this level. It is important to note that pregnancy would typically result in elevated oestradiol concentrations, which is not the case for this patient. Based on the endocrine abnormalities, it is unlikely that this patient has coeliac disease. Overall, the combination of symptoms and laboratory findings strongly suggest a diagnosis of anorexia nervosa.